For the Inventor, By the Inventor

Enter assignee name

Daejeon, South Korea

Alteogen, Inc.

USPTO Granted Patents = 16

% Expired Patents = 12.5

EPO Patents = 10

Forward Citations = 37

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Soon Jae Park (15 out of 16 patents)

Hye-Shin Chung (11 out of 11 patents)

Minsoo Byun (5 out of 5 patents)

4. Sunbae Lee (4 out of 4 patents)

5. Hyung-Nam Song (4 out of 4 patents)

6. Sun-Ah You (4 out of 4 patents)

7. Sang Mee Lee (3 out of 3 patents)

8. Seung Joo Lee (3 out of 6 patents)

9. Chang Woo Lee (3 out of 7 patents)

10. Kyuwan Kim (3 out of 3 patents)

11. Hye Shin Chung (2 out of 2 patents)

12. Jeong Soo Cho (2 out of 2 patents)

13. Yong Mo Kim (2 out of 2 patents)

14. Ji-Sun Kim (2 out of 4 patents)

15. Jin Hwan Kim (2 out of 3 patents)

16 patents: Sort by Forward Citations

1. 12618055 - Hyaluronidase variants with improved stability and pharmaceutical composition comprising the same (2026-05-05),

2. 12570766 - PHARMACEUTICAL COMPOSITION FOR SUBCUTANEOUS ADMINISTRATION CONTAINING HUMAN HYALURONIDASE PH20 VARIANT AND DRUG (2026-03-10),

3. 12371683 - Hyaluronidase variants and pharmaceutical composition comprising the same (2025-07-29),

4. 12221638 - Method for producing recombinant hyaluronidase (2025-02-11),

5. 12090210 - Antibody-drug conjugate comprising modified antibody (2024-09-17),

6. 11981719 - Growth hormone receptor antagonists and fusion proteins thereof (2024-05-14),

7. 11866492 - Antibody specifically binding to FOLR1 and uses thereof (2024-01-09),

8. 11414476 - Method for producing fusion protein having IgG Fc domain (2022-08-16),

9. 11235065 - Antibody-drug conjugate comprising modified antibody (2022-02-01),

10. 9982032 - Stable liquid formulation of fusion protein with IgG Fc domain (2018-05-29),

11. 9902753 - Method of purifying a long-acting human growth hormone (2018-02-27),

12. 9821059 - Composition for stabilizing protein and pharmaceutical formulation comprising the same (2017-11-21),

13. 9814782 - Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same (2017-11-14),

14. 9474803 - Composition for stabilizing fusion protein in which protein and FC domain are fused (2016-10-25),

15. 9051395 - Alpha-1 antitrypsin variant, preparation method thereof and use thereof (2015-06-09),

Company Overview

Alteogen, Inc. is a biotechnology company based in Daejeon, South Korea, specializing in the development of innovative biopharmaceuticals. The company focuses on creating therapeutic proteins and monoclonal antibodies, leveraging advanced technologies in drug formulation and delivery. Alteogen is committed to addressing unmet medical needs through its research in biosimilars and novel biologics, aiming to enhance treatment options for various diseases while contributing to the global healthcare landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

16 Patents

#44 in Daejeon

#742 in South Korea

#37,788 in the World

Daejeon, South Korea

Alteogen, Inc.

Forward Citations = 37

40 inventors:

Soon Jae Park (15 out of 16 patents)

Hye-Shin Chung (11 out of 11 patents)

Minsoo Byun (5 out of 5 patents)

4. Sunbae Lee (4 out of 4 patents)

5. Hyung-Nam Song (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Alteogen, Inc.. Retrieved from https://idiyas.com/company/alteogen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…